Novavax today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK).

The study assessed efficacy during a period with high transmission and with a new UK variant strain of the virus emerging and circulating widely. Novavax also announced successful results of its Phase 2b study conducted in South Africa. The company initiated a rolling submission to the United Kingdom’s regulatory agency, the MHRA, in mid-January. Source: Novavax press release 28/1/2021